No longer trading

Delisted

The delisting was filed on April 29, 2026 (SEC 8-K 3.01). Its last closing price was on May 4, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from April 20, 2026. Source: SEC 8-K 3.01

SGMO

SANGAMO THERAPEUTICS, INC SGMO

NasdaqSmall CapHealthcare

Final 13F Pro quality score

Final rank #2,797 of 2,819 · as of April 20, 2026

Why it scores 9Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$1.44M

Quarter to Mar 31

Net income

$-31.00M

Quarter to Mar 31

Free cash flow

$-19.30M

Quarter to Mar 31

Top Institutional Holders

as of Q2 2026
$29.0K total
NOMURA ASSET MANAGEMENT INTERNATIONAL INC.
$22.0K0.0%
SIMPLEX TRADING, LLC
$4.1KNew
Axiom Investment Management LLC
$1.4K0.0%
FLOW TRADERS U.S. LLC
$1.0K+0.2%
Heritage Investment Group, Inc.
$539New
BARCLAYS PLC
$00.0%
See all 6 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q1 2026
EDGAR

Net Income

Q1 2026
EDGAR

EPS (Diluted)

Q1 2026
EDGAR

Free Cash Flow

Q1 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/SGMO

Earnings Per Share

13fpro.ai/company/SGMO

Loading ratio trend…

SGMO key financials by period

Reported revenue, net income and operating margin by fiscal year, from SANGAMO THERAPEUTICS, INC's annual filings on SEC EDGAR.

SANGAMO THERAPEUTICS, INC reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$39.6M$-122.9M—
FY 2024$57.8M$-97.9M-179.9%
FY 2023$176.2M$-257.8M-155.5%
FY 2022$111.3M$-192.3M-180.8%
FY 2021$110.7M$-178.3M-165.6%
FY 2020$118.2M$-121.0M-109.6%
Source: SGMO filings on SEC EDGAR →

SGMO insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About SANGAMO THERAPEUTICS, INC (SGMO): stock profile, AI score and financials

Delisted: SANGAMO THERAPEUTICS, INC (SGMO) no longer trades and has left 13F Pro's AI-ranked universe. The delisting was filed on April 29, 2026 (SEC 8-K 3.01). Its last closing price was on May 4, 2026. It has left the AI-ranked universe. The score and rank below are its final ones, from April 20, 2026. SANGAMO THERAPEUTICS, INC (SGMO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro tracks SGMO using direct SEC EDGAR data and AI-powered research tools. Based on the latest XBRL financial filings (Q1 2026), SANGAMO THERAPEUTICS, INC reports quarterly revenue of $1.4M, net income of $-31.0M, free cash flow of $-19.3M. Top institutional holders of SGMO by reported 13-F value include NOMURA ASSET MANAGEMENT INTERNATIONAL, SIMPLEX TRADING, Axiom Investment Management, based on the most recent SEC filings. SGMO trades on the Nasdaq exchange and files with the SEC under CIK 1001233. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SGMO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SANGAMO THERAPEUTICS, INC directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1001233 →